The company's lead product
candidate, obeticholic acid, is a bile acid analog and first-in-class
agonist of the farnesoid X receptor. OCA is being developed for a variety of
chronic liver diseases including NASH, primary biliary cirrhosis, portal
hypertension and bile acid diarrhea.
OCA has received orphan drug
designation in both the United States and Europe for the treatment of PBC.
Intercept owns worldwide rights to OCA outside of Japan and China.